Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · Real-Time Price · USD

11.47

-0.09 (-0.78%)

At close: Apr 28, 2025, 4:00 PM

11.03

-0.44 (-3.84%)

Pre-market: Apr 29, 2025, 4:01 AM EDT

Nurix Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Feb '25 Feb 28, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020	2018 - 2019
Revenue	56.42	54.55	76.99	38.63	29.75	17.82	Upgrade
Revenue Growth (YoY)	-30.25%	-29.14%	99.31%	29.84%	66.95%	-42.73%	Upgrade
Cost of Revenue	241.29	221.63	189.15	184.5	116.43	66.49	Upgrade
Gross Profit	-184.87	-167.08	-112.16	-145.87	-86.68	-48.67	Upgrade
Selling, General & Admin	45.8	45.94	42.9	38	31.2	16.31	Upgrade
Operating Expenses	45.8	45.94	42.9	38	31.2	16.31	Upgrade
Operating Income	-230.67	-213.03	-155.06	-183.87	-117.89	-64.98	Upgrade
Interest & Investment Income	22.45	19.73	11.12	3.51	0.82	1.21	Upgrade
Pretax Income	-208.22	-193.3	-143.95	-180.36	-117.06	-63.78	Upgrade
Income Tax Expense	0.18	0.27	-	-	0.13	-20.54	Upgrade
Net Income	-208.4	-193.57	-143.95	-180.36	-117.19	-43.24	Upgrade
Net Income to Common	-208.4	-193.57	-143.95	-180.36	-117.19	-43.24	Upgrade
Shares Outstanding (Basic)	74	67	54	49	43	16	Upgrade
Shares Outstanding (Diluted)	74	67	54	49	43	16	Upgrade
Shares Change (YoY)	36.16%	23.52%	11.79%	13.32%	173.68%	376.03%	Upgrade
EPS (Basic)	-2.81	-2.88	-2.65	-3.71	-2.73	-2.76	Upgrade
EPS (Diluted)	-2.81	-2.88	-2.65	-3.71	-2.73	-2.76	Upgrade
Free Cash Flow	-201.59	-181.86	-89.77	-172.05	-90.03	-4.63	Upgrade
Free Cash Flow Per Share	-2.71	-2.71	-1.65	-3.54	-2.10	-0.30	Upgrade
Gross Margin	-	-	-145.69%	-	-291.38%	-273.14%	Upgrade
Operating Margin	-408.87%	-390.52%	-201.41%	-476.01%	-396.25%	-364.66%	Upgrade
Profit Margin	-369.40%	-354.85%	-186.98%	-466.93%	-393.93%	-242.66%	Upgrade
Free Cash Flow Margin	-357.33%	-333.38%	-116.60%	-445.42%	-302.61%	-26.00%	Upgrade
EBITDA	-222.35	-205.01	-148.93	-179.72	-115.9	-62.8	Upgrade
EBITDA Margin	-	-	-193.45%	-	-	-	Upgrade
D&A For EBITDA	8.32	8.02	6.13	4.15	1.99	2.18	Upgrade
EBIT	-230.67	-213.03	-155.06	-183.87	-117.89	-64.98	Upgrade
EBIT Margin	-	-	-201.41%	-	-	-	Upgrade
Revenue as Reported	56.42	54.55	76.99	38.63	-	-	Upgrade

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q